CS logo
small CS logo
Instytut Hematologii i Transfuzjologii

Warszawa, Poland
Publiczne centrum medyczne w Warszawie

About Instytut Hematologii i Transfuzjologii


Instytut Hematologii i Transfuzjologii – instytut badawczy w Warszawie podległy Ministerstwu Zdrowia specjalizujący się w hematologii i transfuzjologii. Jednostka istnieje od 1951. Do 1992 nosiła nazwę Instytut Hematologii. Obecnie Instytut posiada dwie siedziby: główną na Ursynowie przy ul.
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
7
Takeda
5
Celgene
4
Amgen
3
Astex Pharmaceuticals, Inc.
3
Seagen Inc.
3
Baxalta now part of Shire
2
Karyopharm Therapeutics Inc
2
Pfizer
2
Polish Lymphoma Research Group
2
Rigel Pharmaceuticals
2
Total Rows: 33

Clinical Trials at Instytut Hematologii i Transfuzjologii


During the past decade, Instytut Hematologii i Transfuzjologii conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 22 clinical trials were completed, i.e. on average, 59.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 12 clinical trials were completed. i.e. 150% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years3333121244774433114400222222223366Started TrialsCompleted Trails20152016201720182019202020212022051015
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
2006-03-01
2010-07-01
Completed
676
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
2007-09-01
2011-05-01
Terminated
151
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
2007-11-01
2011-04-01
Terminated
29
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
2009-02-01
2012-01-01
Completed
126
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
2010-06-01
2016-07-25
Completed
488
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
2010-04-30
2020-04-27
Completed
329
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
No longer available
Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery
2011-06-01
2014-04-01
Completed
30

Rows per page:

1–57 of 57

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii" #1 sponsor was "Janssen Research & Development, LLC" with 7 trials, followed by "Takeda" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "Astex Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 33 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii" #1 collaborator was "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator, "Andalusian Network for Design and Translation of Advanced Therapies" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Atlantic Research Group" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.
Created with Highcharts 11.1.0Top Leading SponsorsJanssen Research &Development, LLC: 7Janssen Research &Development, LLC: 7Takeda: 5Takeda: 5Celgene: 4Celgene: 4Amgen: 3Amgen: 3Astex Pharmaceuticals, Inc.: 3Astex Pharmaceuticals, Inc.: 3Seagen Inc.: 3Seagen Inc.: 3Baxalta now part of Shire: 2Baxalta now part of Shire: 2Karyopharm Therapeutics Inc: 2Karyopharm Therapeutics Inc: 2Pfizer: 2Pfizer: 2Polish LymphomaResearch Group: 2Polish LymphomaResearch Group: 2

Created with Highcharts 11.1.0Top CollaboratorsTakeda DevelopmentCenter Americas, Inc.:3Takeda DevelopmentCenter Americas, Inc.:3MillenniumPharmaceuticals, Inc.: 2MillenniumPharmaceuticals, Inc.: 2Andalusian Network forDesign and Translationof Advanced Therapies:1Andalusian Network forDesign and Translationof Advanced Therapies:1AstraZeneca: 1AstraZeneca: 1Atlantic Research Group: 1Atlantic Research Group: 1Bioscience, S.A.: 1Bioscience, S.A.: 1Genentech, Inc.: 1Genentech, Inc.: 1Impact Biomedicines,Inc., a wholly ownedsubsidiary of CelgeneCorporation: 1Impact Biomedicines,Inc., a wholly ownedsubsidiary of CelgeneCorporation: 1Iqvia Pty Ltd: 1Iqvia Pty Ltd: 1Janssen Research &Development, LLC: 1Janssen Research &Development, LLC: 1

Clinical Trials Conditions at Instytut Hematologii i Transfuzjologii


According to Clinical.Site data, the most researched conditions in "Instytut Hematologii i Transfuzjologii" are "Multiple Myeloma" (6 trials), "Acute Myeloid Leukemia" (5 trials), "Leukemia, Myeloid, Acute" (4 trials), "Lymphoma, Non-Hodgkin" (3 trials) and "Acute Myeloid Leukemia (AML)" (2 trials). Many other conditions were trialed in "Instytut Hematologii i Transfuzjologii" in a lesser frequency.

Clinical Trials Intervention Types at Instytut Hematologii i Transfuzjologii


Most popular intervention types in "Instytut Hematologii i Transfuzjologii" are "Drug" (46 trials), "Biological" (6 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (7 trials), "Dexamethasone" (6 trials), "Azacitidine" (5 trials), "Bortezomib" (5 trials) and "Daratumumab" (4 trials). Other intervention names were less common.

Clinical Trials Genders at Instytut Hematologii i Transfuzjologii


The vast majority of trials in "Instytut Hematologii i Transfuzjologii" are 56 trials for "All" genders and 1 trials for "Male" genders.

Clinical Trials Status at Instytut Hematologii i Transfuzjologii


Currently, there are NaN active trials in "Instytut Hematologii i Transfuzjologii". undefined are not yet recruiting, 11 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Instytut Hematologii i Transfuzjologii, undefined suspended trials, and 5 terminated clinical trials to date.
Out of the total trials that were conducted in Instytut Hematologii i Transfuzjologii, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 35Phase 3: 35Phase 2: 12Phase 2: 12Phase 1: 4Phase 1: 4Not Applicable: 1Not Applicable: 1Phase 4: 1Phase 4: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 20Completed: 20Active, not recruiting: 18Active, not recruiting: 18Recruiting: 11Recruiting: 11Terminated: 5Terminated: 5Unknown status: 2Unknown status: 2No longer available: 1No longer available: 1

Departments of Instytut Hematologii i Transfuzjologii


Instytut Hematologii i Transfuzjologii has several departments that took part in Clinical trials: "Institute of Hematology and Transfusion Medicine" - 24 trials, "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" - 10 trials, "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" - 9 trials
Departments List
Name
City
Trials